These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20179595)

  • 21. Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis.
    Fujii M; Karumai T; Yamamoto R; Kobayashi E; Ogawa K; Tounai M; Lipman J; Hayashi Y
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):415-430. PubMed ID: 32238005
    [No Abstract]   [Full Text] [Related]  

  • 22. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
    Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
    Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic antimicrobial agents for postoperative infections: appropriate use of antibiotics from the viewpoint of pharmacokinetic/pharmacodynamic theory].
    Takesue Y; Nakajima K; Wada Y; Ichiki K; Yanagi H; Ikeuchi H
    Nihon Geka Gakkai Zasshi; 2006 Sep; 107(5):224-9. PubMed ID: 17017418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
    Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
    Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical review of echinocandins in pediatric patients.
    VandenBussche HL; Van Loo DA
    Ann Pharmacother; 2010 Jan; 44(1):166-77. PubMed ID: 20009006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice.
    Cohen R; Grimprel E
    Arch Pediatr; 2017 Dec; 24(12S):S6-S8. PubMed ID: 29290237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of dosing regimens and dosing in special populations.
    Sime FB; Roberts MS; Roberts JA
    Clin Microbiol Infect; 2015 Oct; 21(10):886-93. PubMed ID: 25980350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis.
    Li X; Qi H; Jin F; Yao BF; Wu YE; Qi YJ; Kou C; Wu XR; Luo XJ; Shen YH; Zheng X; Wang YH; Xu F; Jiao WW; Li JQ; Xiao J; Dong YN; Du B; Shi HY; Xu BP; Shen AD; Zhao W
    Eur J Pharm Sci; 2021 Aug; 163():105868. PubMed ID: 33951483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Considerations in the pharmacologic treatment and prevention of neonatal sepsis.
    Stockmann C; Spigarelli MG; Campbell SC; Constance JE; Courter JD; Thorell EA; Olson J; Sherwin CM
    Paediatr Drugs; 2014 Feb; 16(1):67-81. PubMed ID: 24218112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antifungal agents under development in children and neonates.
    Steinbach WJ; Benjamin DK
    Curr Opin Infect Dis; 2005 Dec; 18(6):484-9. PubMed ID: 16258320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].
    Bellmann R
    Med Klin Intensivmed Notfmed; 2014 Apr; 109(3):162-6. PubMed ID: 24643839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.